Guidelines For Cancer Treatment During COVID-19 Pandemic

18 December 2020, Version 3

Introduction
These clinical guidelines have been agreed by the Scottish Government’s National Cancer Treatment Response Group. These guidelines are to be used in discussion with patients on a case-by-case basis. The patients should be provided with clear information about any changes in their treatment and why this change has taken place (Updated 20 April 2020).

They align with the majority of similar guidance produced by NHS England: Clinical guide for the management of cancer patients during the coronavirus pandemic (Publications Ref 001559). Variations to these have been agreed in relation to some aspects of SACT, to reflect existing differing service environments in Scotland.

These guidelines will be reviewed and revised regularly.

The risk of COVID-19 is a new factor in harm and benefit considerations for cancer treatment. Increasing prevalence of the virus will compound this. Already, individual cancer treatment decisions are changing to reflect this, in consultation with risk assessments and the expressed preferences of patients.

Treatment pathways will continue to alter significantly, and necessarily, to continue to do no harm.

In that context, vital cancer treatments are expected to continue, and patients can be assured that their clinical teams will continue to offer the best treatment options for them.

Any media enquiries to individual boards about any of this group’s work should be referred directly to SG.

COVID-19 advice
For the latest definitive public advice on COVID-19, please use NHS inform.

Advice for cancer patients, reiterating national advice and where to seek guidance, will be shared with cancer services.

For general information about Coronavirus patients and the public can call 0800 028 2816

The most vulnerable cancer patients
Some people with cancer are more at risk of becoming seriously ill if they contract the coronavirus infection, including people:

- With cancer who are undergoing active chemotherapy or radiotherapy
- With cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment
- Having other targeted cancer treatments which can affect the immune system, such as protein kinase inhibitors or PARP inhibitors.
- Who have had bone marrow or stem cell transplants in the last 6 months, or who are still taking immunosuppression drugs.
In addition to immunosuppression, several factors/co-morbidities are likely to be linked with a poorer prognosis with coronavirus: age over 60; pre-existing cardiovascular disease; and pre-existing respiratory disease.

The more of these individual factors a cancer patient has, the more likely they are to develop a serious illness with coronavirus especially if treated with systemic anti-cancer therapies.

Clinicians may also need to prioritise treatment for those most in need. It is important that all decisions taken are done so with multidisciplinary team (MDT) input and clearly communicated with patients.

**Leadership**

- A consultant must be designated as ‘lead consultant’. This duty can be for one day, a few days or even five days in small units. This is an essential role during crisis management. It cannot be performed by the consultant ‘on-call’. They must be free of clinical duties and the role involves co-ordination of the whole service from emergency department (ED) through to liaison with other specialties and managers.
- It can be very stressful during a crisis. Support each other and share the workload. Do not expect the clinical director to do all the co-ordination.
- Make contingency plans for supply chain issues.
- There should be a system in place to provide chief executives with the option of oversight and input *(Updated 20 April 2020)*

**Surgical patients**

If appropriate, MDTs may consider non-surgical options, including prolongation of neoadjuvant treatment and non-surgical treatment if the outcomes are similar.

**Categorisation of patients**

- **Priority level 1a**
  Emergency: operation needed within 24 hours to save life

- **Priority level 1b**
  Urgent: operation needed with 72 hours
  Based on: urgent/emergency surgery for life threatening conditions such as obstruction, bleeding and regional and/or localised infection permanent injury/clinical harm from progression of conditions such as spinal cord compression

- **Priority level 2**
  Elective surgery with the expectation of cure, prioritised according to:
  
  within 4 weeks to save life/progression of disease beyond operability based on:
  - urgency of symptoms
  - complications such as local compressive symptoms
  - biological priority (expected growth rate) of individual cancers

- Local complications may be temporarily controlled, for example with stents if surgery is deferred and/or interventional radiology.
• **Priority level 3**
  Elective surgery can be delayed for 10-12 weeks with no predicted negative outcome.

**General measures to consider**

All complex cancer surgery will require level 1 support routinely. There is a small risk of postoperative complications requiring return/admission to ITU in (usually) the first week.

Separation of the location of emergency from elective operations within the same Board may allow elective work to continue at one site.

If appropriate, MDTs may consider non-surgical options, including prolongation of neoadjuvant treatment and non-surgical treatment if the outcomes are similar.

Providing patients with realistic messaging around outcomes which are likely to be affected. *(Updated 20 April 2020)*

**Systemic anti-cancer treatments**

Treatment decisions will need to be made on a case-by-case basis with input from both patients and the MDT. The prioritisation details should be overseen by the nominated haematology-oncology leads.

**General approach to prioritising patients on systemic anti-cancer therapy:**

- Categorise patients by treatment intent and risk-benefit ratio associated with treatment.
- Consider alternative and less resource-intensive treatment regimes.
- Seek alternative methods to monitor and review patients receiving systemic therapies.

Clinicians will also need to consider the level of immunosuppression associated with an individual therapy and the condition itself, and patients' other risk factors.

**General measures to consider**

Consider whether systemic therapies can be given in alternative regimens, different locations or via other modes of administration to minimise patient exposure and maximise resources. The impact on and resilience of the supply chain must be confirmed before implementing a change.

1. Changing intravenous treatments to subcutaneous or oral if there are alternatives.
2. Selecting regimens that are shorter in duration.
3. Consider using 4-weekly or 6-weekly immunotherapy regimens rather than 2-weekly and 3-weekly.
4. Consider alternative models for supply of oral systemic anticancer treatments to minimise hospital attendance.
5. Consider use of G-CSF in patient groups currently not receiving this routinely, where there is evidence of clinical benefit in order to protect patients and reduce admission rates. (Noting that G-CSF does not provide protection from viral infections including Covid-19.)
6. Considering treatment breaks for long-term treatments when risk of coronavirus is high.
7. Consider what supportive services are required to deliver regimens safely.
Seek alternative methods to educate, monitor and review patients on systemic therapies. Identify alternative arrangements to minimise patient exposure. This could involve patients having blood tests locally or telephone/virtual appointments.

All patients should be fully informed of their individual treatment plan, and any changes made to their original treatment plans. Consent must be provided by the patient. Consent must be comprehensively documented as processes may vary between patients. Proof of consent is mandatory by way of a patient signature or equivalent proof. (Updated 20 April 2020)

**New Governance Arrangements**
(Added 20 April 2020)

**Background**
The Covid-19 pandemic changes the balance of benefit to risk for patients receiving systemic anticancer therapy (SACT) and will impact on workforce available to deliver SACT services in NHS Scotland.

There is an urgent need to review prescribing practice in order to minimise risk to patients, optimise use of workforce and support planning for SACT services being compromised due to staff absences and/or supply chain shortages.

Decisions on treatment will need to be made on an individual patient basis by clinicians in discussion with the patient and, where appropriate, the multidisciplinary team (MDT). There will also be decisions made which will apply to groups of patients, notwithstanding that individual documented patient discussions will still be required Normal processes for organisational approval of routine changes to practice are not sufficiently responsive to the current situation and are also currently suspended.

This governance framework outlines the interim arrangements in NHS Scotland for oversight of proposed changes to adult SACT practice in the context of COVID-19. This will be delivered through a collaboration of the three regional cancer networks, to facilitate rapid decision-making and support, as far as possible, consistency in these changes.

**Key Principles**
- The purpose of the interim framework is to:
  - facilitate a consistent approach to decision-making on cancer medicines in the context of COVID-19
  - support planning for SACT services being compromised due to staff absences and/or supply chain shortages
- The framework will be delivered through a collaboration of the three regional cancer networks.
- The framework will apply to decisions on interim routine practice for groups of patients. The normal process for individual requests will remain aligned with Board medicines’ governance processes.
- Boards will still need to consider local governance issues and the service/budget impact of changes.
- There may be treatment options that are off label, not considered cost effective and/or have significant budget impact but, during the pandemic, will be a clinically safer option for patients.
- All interim changes to practice will be reviewed once normal services are resumed. Protocols and guidelines will be given a nominal one year review but may be changed or withdrawn earlier than this.
• The interim framework process will be endorsed by Boards with the national group having delegated responsibility for decisions.
• A ‘Once for Scotland’ approach should be taken unless there are specific circumstances that require a more urgent regional or Board level decision.
• Regions and Boards who make urgent changes in response to local situations will still inform the national group of these changes. It is recommended that local and/or regional decision making groups are set up applying the same principles as the national group.
• A decision will be subject to confirmation that a supply assessment has been undertaken and there is sufficient supply to support the change.
• A decision log will be held of all national, regional and local decisions to facilitate review when normal services resume.
• Regular reporting of changes to the National COVID-19/Cancer Treatment Response Group

Process

• A COVID 19 National Cancer Medicines Advisory Group (COVID 19 NCMAG) has been convened.
• Individual consultants wishing to implement a change should seek team/MCN support in the first instance.
• Submissions to the COVID 19 NCMAG for changes to practice will be led by a tumour site team lead working in collaboration with consultant colleagues across NHS Scotland.
• Pharmacy support to work up submissions will be provided.
• Evidence & documentation requirements
  o Proforma(s) to be developed with key requirements:
    • Justification for change in the context of COVID-19
    • Prioritisation category as defined in SGHD Guidelines for cancer treatment during COVID 19 pandemic 20 March 2020, Version 1
    • Brief summary of evidence base
    • Patient population this applies to
      o SACT protocol and/or interim SACT pathway as appropriate
  • The nominated lead will submit the proposal for consideration.
  • The professional secretary, working with National Procurement, will ensure a supply assessment has been undertaken and there is sufficient supply to support the change.
  • Proposals to be reviewed by the group at regular virtual meetings.
  • Communication of decision to the nominated cancer network lead and requesting clinician.

Membership

• Chair – cancer centre Clinical Director (CD) or SACT Lead Clinician
• Professional Secretary - a Cancer Network Pharmacist
• All three Regional Cancer Network Pharmacists (or nominee)
• Clinical Director or SACT lead clinician representative from each network (one of which will chair) – at least one CD and one SACT lead clinician
• Director of Pharmacy representative
• Cancer centre manager representative

The professional secretary will be supported by the Healthcare Improvement Scotland Off-label Cancer Medicines programme team who will be redeployed to support the group.

Deputies will be identified and quorum defined as at least one representative from each network.
Implementation

- All cancer networks and Boards are expected to ensure practice is aligned to the advice from the group unless there are exceptional circumstances.
- Regional Cancer network lead to:
  - cascade the decision and links to associated documents to their constituent boards
  - inform the Chemotherapy Electronic Prescribing and Administration System clinical support team(s).
- NHS boards to:
  - act on the decisions and advice from the national group and ensure relevant staff are aware of the decisions.
  - cascade information and links to associated documents through local SACT groups and teams

Radiation Therapy

Categorisation of patients

- **Priority level 1**
  Patients with category 1 (rapidly proliferating) tumours currently being treated with radical (chemo)radiotherapy with curative intent where there is little or no scope for compensation of gaps.
  Patients with category 1 tumours in whom combined External Beam Radiotherapy (EBRT) and subsequent brachytherapy is the management plan and the EBRT is already underway.
  Patients with category 1 tumours who have not yet started and in whom clinical need determines that treatment should start in line with current cancer waiting times.

- **Priority level 2**
  Urgent palliative radiotherapy in patients with malignant spinal cord compression who have useful salvageable neurological function.

- **Priority level 3**
  Radical radiotherapy for Category 2 (less aggressive) tumours where radiotherapy is the first definitive treatment.
  Post-operative radiotherapy where there is known residual disease following surgery in tumours with aggressive biology.

- **Priority level 4**
  Palliative radiotherapy where alleviation of symptoms would reduce the burden on other healthcare services, such as haemoptysis.

- **Priority level 5**
  Adjuvant radiotherapy where there has been compete resection of disease and there is a <20% risk of recurrence at 10 years, for example most ER positive breast cancer in patients receiving endocrine therapy.
  - Radical radiotherapy for prostate cancer in patients receiving neo-adjuvant hormone therapy.

General measures to consider

In all cases, the most clinically appropriate hypofractionated schedule should be used, for example single 8Gy fraction for malignant spinal cord compression (MSCC).

For adjuvant breast radiotherapy 26Gy in 5 fractions is isotoxic compared with 40.05Gy in 15 fractions and may mitigate a deferred start date in patients with node negative breast cancer.
Offer omission of adjuvant breast radiotherapy to those patients with low risk breast cancer who fulfil the NICE Early Breast Cancer Guideline (2018) criteria.

Anaesthetic availability may be the determining factor for capacity for some radiotherapy including gynae brachytherapy, TBI and paediatrics.

In all cases, the most clinically appropriate hypofractionated schedule should be used, for example single 8Gy fraction for malignant spinal cord compression (MSCC).

**General measures across all services to minimise risk and maximise workforce capacity**

- Where treatments are required to be postponed, an appropriate local system to capture these individuals must be in place. This will ensure the individuals are prioritised and receive their treatment at the soonest possible opportunity during the recovery phase. (Updated 20 April 2020)
- In order to protect the workforce and patients, individual centres can take a proactive action to ensure all appropriate PPE is available. Please contact the Scottish Government by email at covid-19-health-PPE@gov.scot (Updated 20 April 2020)
- In order to increase workforce capacity, individuals registered with a professional practice within the past 3 years and under the age of 70 can apply to the registers through an expedited process.
- Minimise face-to-face appointments – Offer consultations via telephone or video consultation wherever possible.
  - Cut non-essential follow-up visits.
  - Accelerate adoption of stratified follow-up models.
  - Home delivery of oral systemic agents where suitable/available.
- Reduce dwell time in services – for those who do still need to attend, particularly for treatment, schedule appointments to reduce waiting times.
- Encourage patients not to arrive early – consider measures such as texting them when ready to see them so they can wait in their car.
- Follow broader Board actions and protocols including testing and isolation of patients with coronavirus symptoms.
- If staff are required to self-isolate due to contact with a confirmed case of coronavirus, consider ways they can continue to provide care and/or support MDTs. For example:
  - Virtual attendance at MDT meetings
  - Telephone or video consultations, especially follow-ups
  - Identifying vulnerable patients and making contact to discuss changes to care and treatment
  - Identifying patients suitable for remote monitoring/follow-up
  - Data entry (where remote access enabled).

**Overall considerations**

- Where possible, staff and patients should be cohort. Ideally patients attending for pre-SACT blood test will do so at a site separate from the local NHS facility accepting suspected COVID-19 admissions. Pre-SCAT blood tests should otherwise continue as clinically appropriate. (Updated 20 April 2020)
- New recruitment to clinical trials will generally be paused, but exceptions may be made locally. (Updated 20 April 2020)
- We should avoid unproductive attendances at hospital.
• Senior decision-making at the first point of contact should reduce or even prevent the need for further attendances.
• A decrease in elective work will allow for a greater senior presence at the front door.
• Clinicians may need to work in unfamiliar environments or outside of their sub-specialist areas. They will need to be supported.
• No patient should be scheduled for surgery without discussion with a consultant.
• The longer hours will allow ED access and help reduce crowding in waiting rooms.
• The possibility of a seven-day service may need to be considered.
• Consider postponing long-term follow-up patients until the crisis has passed.
• Can a follow-up virtual clinic be developed with your facility?
• CT scanning may be limited as it is the investigation of choice for coronavirus pneumonitis.